---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005040"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2022-03-30T23:59:59+00:00"
generated_at: "2026-06-26T13:37:15.327761+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports 2021 results; cash $271.6M, BDC-1001 on track for RP2D in 2022

## Summary
- Cash, cash equivalents, and marketable securities $271.6M at Dec 31, 2021 vs $22.8M at end 2020; runway into 2024.
- Collaboration revenue $1.3M for FY 2021 from Genmab R&D collaboration (vs $0.2M in 2020).
- R&D expenses $75.7M, G&A $18.4M; operating loss $92.8M for FY 2021.
- BDC-1001 (HER2) Phase 1/2 on track for recommended Phase 2 dose in 2022; Opdivo combo arm dosed first patient Dec 2021.
- Preclinical data on BDC-2034, BDC-3042, and PD-L1 ISAC to be presented at AACR 2022.

## SEC filing metadata
- accession: 0000950170-22-005040
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2022-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017022005040/0000950170-22-005040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017022005040/bolt-20220330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005040
- JSON: https://secwatch.observer/filing/0000950170-22-005040.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.